evidence: The first time mRNA has been used as a vaccine platform was initially established by the Weissman group to develop a zika virus vaccine (Pardi et al., 2017). Pfizer-BioNTech developed BNT162b1 and BNT162b2 vaccines against SARS-CoV-2. BNT162b1 is a SARS-CoV-2 spike protein RBD encoding modified messenger RNA (mRNA) incorporating 1-methyl-pseudourine, which dampens innate immune sensing to induce mRNA translation. The RBD antigen is modified by the addition of a T4 fibritin-derived "foldon" trimerization domain to increase its immunogenicity by multivalent display (Mulligan et al., 2020). The other candidate, BNT162b2, encodes the full-length SARS-CoV-2 spike protein with two proline changes that lock it in the prefusion conformation and make it more closely mimic the intact virus to elicit prominent virus-neutralizing antibodies. Apart from mRNA (30 μg), the Pfizer-BioNTech vaccine includes lipids and cholesterol, potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose. Storage is -70°C to -80°C; later, as an alternative, -25°C to -15°C was advised for 2 weeks (Polack et al., 2020). The European Medicines Agency (EMA) as a National Regulatory Authority (NRA) approved it, and later it was approved by WHO after evaluating the data on clinical trials (www.pfizer.com).